Uma doença inflamatória que começa na idade adulta, afetando apenas homens. É causada por mutações genéticas que ocorrem nas células do corpo durante a vida da pessoa, e não são herdadas. A doença se manifesta por sintomas reumatológicos (problemas nas juntas, músculos e tecidos conectivos) que aparecem na idade adulta, em média aos 64 anos. Os sintomas incluem febres recorrentes (que voltam sempre), inflamações nos pulmões e na pele, inflamação dos vasos sanguíneos (vasculite), coágulos de sangue em veias mais profundas (trombose venosa profunda), dores nas articulações e inflamação da cartilagem das orelhas e do nariz. Exames de laboratório mostram alterações no sangue, como um tipo de anemia em que as células vermelhas são maiores que o normal (anemia macrocítica), e níveis elevados de marcadores de inflamação. Cerca de metade dos pacientes apresenta autoanticorpos positivos (o sistema imunológico ataca o próprio corpo). A biópsia da medula óssea revela alterações nas células imaturas que dão origem aos glóbulos brancos e vermelhos, com a presença de pequenas bolhas ou espaços vazios (vacuolização degenerativa). Também são observadas diferentes dificuldades na formação e no desenvolvimento normal das células sanguíneas. A condição não responde aos medicamentos usados para tratar doenças reumatológicas e suas características podem levar a uma morte precoce.
Introdução
O que você precisa saber de cara
Uma doença inflamatória que começa na idade adulta, afetando apenas homens. É causada por mutações genéticas que ocorrem nas células do corpo durante a vida da pessoa, e não são herdadas. A doença se manifesta por sintomas reumatológicos (problemas nas juntas, músculos e tecidos conectivos) que aparecem na idade adulta, em média aos 64 anos. Os sintomas incluem febres recorrentes (que voltam sempre), inflamações nos pulmões e na pele, inflamação dos vasos sanguíneos (vasculite), coágulos de sangue em veias mais profundas (trombose venosa profunda), dores nas articulações e inflamação da cartilagem das orelhas e do nariz. Exames de laboratório mostram alterações no sangue, como um tipo de anemia em que as células vermelhas são maiores que o normal (anemia macrocítica), e níveis elevados de marcadores de inflamação. Cerca de metade dos pacientes apresenta autoanticorpos positivos (o sistema imunológico ataca o próprio corpo). A biópsia da medula óssea revela alterações nas células imaturas que dão origem aos glóbulos brancos e vermelhos, com a presença de pequenas bolhas ou espaços vazios (vacuolização degenerativa). Também são observadas diferentes dificuldades na formação e no desenvolvimento normal das células sanguíneas. A condição não responde aos medicamentos usados para tratar doenças reumatológicas e suas características podem levar a uma morte precoce.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 11 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 25 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Not applicable.
Catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation through the ubiquitin-proteasome system (PubMed:1447181, PubMed:1606621, PubMed:33108101). Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP (PubMed:1447181). Essential for the formation of radiation-induced foci, timely DNA repair and for respon
CytoplasmMitochondrionNucleus
Spinal muscular atrophy X-linked 2
A lethal infantile form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Clinical features include hypotonia, areflexia, and multiple congenital contractures.
Variantes genéticas (ClinVar)
186 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 11 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
3 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Síndrome VEXAS
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
6 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
9 ensaios clínicos encontrados, 7 ativos.
Publicações mais relevantes
Inflammatory cell death and monocyte dysfunction in VEXAS syndrome.
VEXAS syndrome is a severe adult-onset autoinflammatory disease caused by somatic mutations in the UBA1 gene, disrupting cytoplasmic ubiquitin-activating enzyme E1 function in hematopoietic progenitors. Its pathogenesis remains poorly understood, particularly the mechanisms by which UBA1 mutations disrupt myeloid cell function in the context of inflammatory stimuli. Here, we combine a genetically engineered THP-1 monocytic model with ex vivo analyses of blood and tissue samples from VEXAS patients to investigate the consequences of the canonical UBA1M41V mutation. We show that UBA1-mutated monocytes exhibit TNF-α-induced cell death, characterized by RIPK1 phosphorylation, and MLKL- and caspase-8-mediated cell death. Importantly, we extend these findings to patient-derived CD14⁺ sorted cells, confirming that these cells undergo aberrant apoptotic and necroptotic cell death. Mechanistically, activation of these cell death pathways appears to be promoted by defective NF-κB-dependent transcriptional responses and reduced cFLIP(L) expression following TNF-α stimulation. UBA1-mutated monocytes also display blunted cytokine responses to Toll-like receptor (TLR) agonists despite preserved TLR expression, linked to an impaired NF-κB response. UBA1M41V-derived macrophages exhibit a pro-inflammatory transcriptional profile with increased chemokine secretion that promotes monocyte recruitment. In addition, these UBA1-mutated macrophages display impaired efferocytosis due to lysosomal dysfunction. Together, these findings reveal a pathogenic axis in VEXAS syndrome linking UBA1 loss of function and defective ubiquitination to RIPK1-mediated inflammatory cell death, impaired antimicrobial signaling, and defective resolution mechanisms. Our study provides novel mechanistic insights into the myeloid dysfunction underlying inflammation and cytopenia in VEXAS and supports the therapeutic targeting of inflammatory cell death pathways.
VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a monogenic disease of adulthood characterised by treatment-refractory systemic inflammation and progressive bone marrow failure. VEXAS syndrome is caused by acquired mutations in the UBA1 gene that are restricted to haematopoietic cells. Men aged 50 years or older are particularly susceptible to VEXAS syndrome, with prevalence estimates of approximately one in 4000 men. Perturbation of UBA1, the master enzyme of cellular ubiquitination, promotes myeloid-driven inflammation that is difficult to control with medications other than glucocorticoids. Cytokine-directed therapies (ie, IL-6 and JAK inhibitors) might temporise symptoms and allow glucocorticoid reduction. Hypomethylating agents (ie, azacytidine) can induce clinical and molecular remission in some patients, but are associated with substantial toxicities. Haematopoietic cell transplant might be effective treatment in patients who are suitable candidates. The discovery of VEXAS syndrome highlights the potential role of somatic mutations in complex inflammatory diseases.
Reversal of third-degree AV block with ruxolitinib in VEXAS-associated myocarditis: a case report.
VEXAS syndrome is a newly described autoinflammatory condition; cardiac involvement is exceedingly rare. This case illustrates a reversible complete heart block due to myocarditis in VEXAS, successfully treated with targeted therapy. A 69-year-old man with known VEXAS syndrome presented with dizziness and syncope. Workup revealed third-degree atrioventricular (AV) block and imaging consistent with myocarditis. Standard therapy (atropine, isoprenaline infusion) stabilized the patient, and ruxolitinib (a JAK inhibitor) was initiated alongside corticosteroids to treat the underlying inflammatory syndrome. Within days, the patient's AV conduction was restored without the need for pacemaker insertion. He was discharged with improved cardiac function and ongoing immunomodulatory therapy. Targeted immunomodulation can reverse cardiac conduction block caused by inflammation in VEXAS syndrome. This case underscores the importance of recognizing autoinflammatory syndromes as a cause of heart block and suggests a potential role for JAK inhibitors in treating inflammatory myocarditis.
Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome.
Somatically acquired mutations in the E1 ubiquitin-activating enzyme UBA1 within haematopoietic stem and progenitor cells (HSPCs) were recently identified as the cause of the adult-onset autoinflammatory syndrome VEXAS (vacuoles, E1 enzyme, X linked, autoinflammatory, somatic)1. UBA1 mutations in VEXAS lead to clonal expansion within the HSPC and myeloid, but not lymphoid, compartments. Despite its severity and prevalence, the mechanisms by which UBA1 mutations cause multiorgan autoinflammation and haematological disease are unclear. Here we use somatic gene-editing approaches to model VEXAS-associated UBA1 mutations in primary macrophages and HSPCs. Uba1-mutant mouse macrophages exposed to inflammatory stimuli underwent aberrant apoptotic and necroptotic cell death mediated by caspase-8 (CASP8) and RIPK3-MLKL, respectively. Accordingly, in mice challenged with TNF or LPS, the UBA1 inhibitor TAK-243 exacerbated inflammation in a RIPK3-CASP8-dependent manner. By contrast, Uba1 mutation in HSPCs induced an unfolded protein response and myeloid bias independently of RIPK3-CASP8. Mechanistically, aberrant cell death of Uba1-mutant macrophages coincided with a kinetic defect in Lys63/Met1 (that is, linear) polyubiquitylation of inflammatory signalling complexes. Collectively, our results link VEXAS pathogenesis to the pathogenesis of rarer monogenic autoinflammatory syndromes, highlight specific ubiquitin-associated defects stemming from an apical mutation in the ubiquitylation cascade and support therapeutic targeting of the inflammatory cell death axis in VEXAS.
Unravelling the cellular mechanisms of VEXAS syndrome.
Publicações recentes
Unmasking Vexas Syndrome: A Rare Case with Crescentic Glomerulonephritis.
When to suspect monogenic autoinflammatory diseases in patients with digestive symptoms?
Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.
📚 EuropePMC482 artigos no totalmostrando 195
VEXAS syndrome in adults: A narrative review of genomic pathogenesis, multisystem phenotypes, diagnostic algorithms, and emerging therapeutic strategies.
Autoimmunity reviewsVEXAS Syndrome with an Improvement of Chest Shadows Without Immunosuppressive Therapy: A Case Report.
Internal medicine (Tokyo, Japan)Large-Vessel Vasculitis With Autoimmune Myelodysplastic Syndrome: An Uncommon Case of Large-Vessel Vasculitis With Cytopenia That Is Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic Syndrome (VEXAS) Negative.
CureusInflammatory cell death and monocyte dysfunction in VEXAS syndrome.
BloodA case of VEXAS syndrome presenting as macrophage activation syndrome: from chronic inflammation to multi-organ failure.
Internal and emergency medicinePAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.
Journal of clinical medicineNavigating through uncertainty-Experience from the UK national VEXAS MDT.
British journal of haematologyIn response to Bergonzi et al.: Azacitidine-ruxolitinib combination therapy may permit dose reduction in VEXAS syndrome.
British journal of haematologyCase Report: Early-onset VEXAS syndrome with recurrent pulmonary inflammation and myelodysplasia: a diagnostic and therapeutic challenge.
Frontiers in immunologyExpanding the Clinical Spectrum of VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome: The First Report of Histologically Confirmed Neutrophilic Colitis With Rare Muscular and Pancreatic Involvement.
CureusA vexing fever: Unveiling VEXAS syndrome.
The American journal of medicineBeyond Sweet Syndrome: Untangling the Threads of Histiocytoid Sweet Syndrome and Cutaneous Myeloid Neoplasia.
Surgical pathology clinicsCase Report: Diagnostic challenges in VEXAS syndrome with novel ultrastructural lung findings: IgG4-RD and vasculitis as relevant differential diagnoses.
Frontiers in immunologyRheumatology 2050: How our specialty is changing.
Future healthcare journalA fatal case of VEXAS syndrome with a brief review.
Journal of vascular surgery cases and innovative techniquesVEXAS syndrome and cancer: Insights about a possible "Tip of the Iceberg". Ambidirectional data from the international AIDA network registries.
Seminars in arthritis and rheumatismClinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registries.
Frontiers in medicineHemi-Orolingual Angioedema in a Patient With VEXAS Syndrome.
EJHaemManaging Metastatic Cutaneous Squamous Cell Carcinoma in VEXAS Syndrome: A Therapeutic Challenge.
Clinical and experimental dermatologyRapid cutaneous remission response to tofacitinib and systemic corticosteroids in VEXAS syndrome with a novel UBA1 mutation.
JAAD case reportsCharacteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.
LeukemiaOrbital inflammation in VEXAS syndrome.
The British journal of ophthalmologyHypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review.
British journal of haematologyVEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
Lancet (London, England)Reversal of third-degree AV block with ruxolitinib in VEXAS-associated myocarditis: a case report.
European heart journal. Case reportsA Case of VEXAS Syndrome.
WMJ : official publication of the State Medical Society of WisconsinMorphologic Deciphering of Hematopoietic Cell Vacuolization: Lessons From VEXAS Syndrome and Other Etiologies.
International journal of laboratory hematologyA rare case of VEXAS syndrome.
Rheumatology advances in practiceVEXAS Syndrome with Vibrio vulnificus Sepsis During Treatment with Tocilizumab: A Case Report.
Internal medicine (Tokyo, Japan)A Case of VEXAS Syndrome Initially Masked as Myelodysplastic Syndrome: Importance of Marrow Vacuolization and UBA1 Testing: A Case Report.
The American journal of case reportsA Vexing Diagnosis: ENT Presentation of Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome.
CureusPolyarteritis nodosa associated with VEXAS syndrome and chronic myelomonocytic leukemia: a case-control study.
Rheumatology (Oxford, England)VEXAS syndrome with cochleovestibular involvement.
Auris, nasus, larynxVEXAS syndrome in rheumatology practice: features from a multicenter cohort in north-east Italy.
Frontiers in immunology[VEXAS syndrome mimicking relapsing polychondritis: A case report].
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesCase Report: VEXAS syndrome with extensive pulmonary, cardiac, and skeletal involvement.
Frontiers in immunologySafety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.
British journal of haematologyImmunogenetics of Behçet's disease: Is there a link to recent phenotypic changes?
Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyRefining the interpretation of drug survival and safety in VEXAS syndrome: the importance of competing risks and exposure time. Comment on the article by Eviatar et al.
Arthritis & rheumatology (Hoboken, N.J.)Unravelling the cellular mechanisms of VEXAS syndrome.
Nature reviews. RheumatologyVEXAS Syndrome Presenting With Pleuritis.
Clinical case reportsReinterpreting the efficacy of IL-1 inhibitors in VEXAS syndrome: a matter of superiority or sequencing?: comment on the article by Eviatar et al.
Arthritis & rheumatology (Hoboken, N.J.)VEXAS syndrome with eosinophilia and pathologically mimicking histiocytosis: a case report.
Modern rheumatology case reportsEstablishing a consensus definition of VEXAS flare for clinical research.
Rheumatology (Oxford, England)Is the combination of Myelodysplastic syndromes and pulmonary fibrosis accidental or inevitable?
Multidisciplinary respiratory medicineMonitoring Variant Allele Fraction in VEXAS Syndrome: A Comparison of Digital PCR and Next-Generation Sequencing.
EJHaem[What is an undifferentiated systemic autoinflammatory disease in adults? Current state of knowledge in 2025].
La Revue de medecine interneTargeting IL-1 in Autoinflammatory Syndromes: Lessons From Canakinumab and VEXAS Syndrome.
International journal of rheumatic diseasesUnravelling the Puzzle: Highlighting a Case of VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Mimicker Presented With Inflammatory Symptoms and Pancytopenia.
CureusThe MAGIC (Mouth and Genital Ulcers With Inflamed Cartilage) of VEXAS: A Case of Overlap Between Behçet Disease and VEXAS Syndrome.
The Journal of rheumatologyVEXAS Syndrome Presenting as Erythema Nodosum and Pancytopenia: Diagnostic Utility of 18F-FDG PET/CT in Systemic Inflammation.
Clinical nuclear medicineVasculitis associated with haematologic malignancies.
Current opinion in rheumatologyVEXAS syndrome presenting with features of Sjögren's disease: a case-based review of VEXAS and autoimmune disease overlap.
Clinical rheumatologyPhenotypes of patients with more than one autoinflammatory disease-associated gene variant: overlapping and mixed autoinflammatory disorders.
Rheumatology (Oxford, England)VEXAS syndrome: cutaneous manifestations and UBA1 gene variants in the diagnosis of a rare autoinflammatory syndrome - Case report.
Anais brasileiros de dermatologiaIndependent mechanisms of inflammation and myeloid bias in VEXAS syndrome.
NatureNeutrophils take center stage in VEXAS syndrome pathogenesis.
The Journal of clinical investigationDecoding VEXAS syndrome: emerging insights into pathogenesis and clinical management.
Current opinion in rheumatologyJoint involvement in VEXAS and non-VEXAS clonal haematopoiesis: two clusters from a multicentre regional cohort.
RMD openVEXAS syndrome in a patient with seropositive rheumatoid arthritis: lessons in diagnostic vigilance.
BMJ case reportsHistiocytoid Sweet Syndrome - A systematic literature review of the clinical and histological characteristics and treatment outcomes.
Journal of the European Academy of Dermatology and Venereology : JEADVInterval Changes in Hematopoietic Vacuolization in VEXAS Syndrome with M41T Mutation: Insights into Diagnosis and Disease Progression.
Clinical laboratoryPrimary CD34+ cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.
British journal of haematologyDistinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.
LeukemiaHigh glucocorticoid dependency and limited therapeutic response in Japanese patients with VEXAS syndrome: a multicentre retrospective study.
Modern rheumatologyRespiratory-Predominant Relapsing Polychondritis: The Role of Pet Scan in Making this Challenging Diagnosis.
European journal of case reports in internal medicineA Patient with Vexas Syndrome Presenting with Complete Ophthalmoplegia.
European journal of case reports in internal medicineSkin Manifestations in VEXAS Syndrome: Specific Clonal Infiltrates versus Non-Specific Reactive Findings.
Case reports in dermatologyPeriorbital oedema, trismus, myalgia as muscular manifestations of VEXAS syndrome: a case report and narrative literature review.
Rheumatology (Oxford, England)Coexistence of VEXAS Syndrome and Chronic Hepatitis B Virus Infection: a Case Report and Literature Review.
Clinical reviews in allergy & immunologyDiagnostic and Monitoring Strategies for VEXAS Syndrome: Evaluating Sanger Sequencing, NGS, and the SWIM-Score.
Journal of clinical immunologyClinical-Pathological Conference Series from the Medical University of Graz : Case No 183: A 57-year-old farmer with fever, cough, maculopapular rash and bicytopenia.
Wiener klinische WochenschriftSubconjunctival Lesion in VEXAS Syndrome: Expanding the Ocular Disease Spectrum.
Ophthalmic plastic and reconstructive surgeryCharacterizing VEXAS syndrome in women: Findings from an international multicenter study.
Journal of internal medicineJAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases.
Dermatology research and practiceComparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study.
Arthritis & rheumatology (Hoboken, N.J.)Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden.
Arthritis & rheumatology (Hoboken, N.J.)Clinicopathological Challenge: Fixed Urticaria-Like Pink Papules in a Patient With Recurrent Fevers and Arthralgias.
International journal of dermatologyAzacitidine as therapy for VEXAS syndrome.
BloodVEXAS syndrome: more than just vacuoles.
Hematology, transfusion and cell therapy[Immuno'logical (The scientific updates you wouldn't dare to read anywhere else): The hidden face of VEXAS syndrome].
La Revue de medecine interneCancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians.
Journal of clinical medicineVEXAS Syndrome and Substance Use Disorders: A Large-Scale, Propensity-Matched, Case-Control Analysis Revealing Immune-Mediated Comorbidities.
International journal of dermatologyDiagnostic persistence in geriatric medicine: A case of VEXAS syndrome in an older adult.
Geriatrics & gerontology internationalA complex case of recurrent bilateral alternating orbital inflammation associated to VEXAS syndrome.
Orbit (Amsterdam, Netherlands)Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention.
The Lancet. RheumatologyVEXAS syndrome and immune-mediated rheumatic diseases: overlaps in clinical features and mechanisms.
The Lancet. RheumatologyExtensively distributed erythema nodosum in VEXAS syndrome.
The Lancet. HaematologyUBA1-depleted neutrophils disrupt immune homeostasis and induce VEXAS-like autoinflammatory disease in mice.
The Journal of clinical investigationFrom diagnostic uncertainty to targeted therapy: a case-based review of VEXAS syndrome.
Rheumatology international[Treatment for VEXAS syndrome with luspatercept combined with cyclosporine A, methylprednisolone, and thalidomide: a case report].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiVacuolated Marrow Cytopenias from Copper Deficiency to UBA1-Mutant VEXAS: Molecular Landscape, Systematic Review, and Cost-Efficient Diagnostic Algorithm.
International journal of molecular sciencesVEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies.
International journal of molecular sciencesPrevalence and outcome of VEXAS syndrome in unrelated hematopoietic cell transplantation for bone marrow failure.
Clinical and experimental medicineVacuoles, E1 Enzyme, X-linked, Auto-Inflammatory, Somatic (VEXAS) Syndrome Causing Acute Lower Limb Ischaemia.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular SurgeryDiagnostic performance of four proposed algorithms for suspected VEXAS syndrome.
Rheumatology (Oxford, England)Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, and Somatic (VEXAS) Syndrome Presenting With Bicytopenia and Vasculitis.
CureusVEXAS: A review of current understandings and emerging treatment strategies.
Frontiers in immunologyAmerican College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.
Arthritis & rheumatology (Hoboken, N.J.)Bone marrow vacuolization to curative strategies: Evolving paradigms in VEXAS syndrome management.
Current research in translational medicineA cross-sectional survey on VEXAS syndrome: insights from a global expert panel.
Clinical rheumatologyIs immunotherapy safe and effective in patients with VEXAS syndrome?
Journal for immunotherapy of cancerRecent progress in clonal hematopoiesis: expanding the concept.
International journal of hematologyImpaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome.
BloodPromise of Jak Inhibition in the Management of VEXAS, Case Report with Review of the Literature.
Open access rheumatology : research and reviewsDeveloping efficient predictive models for the diagnosis of VEXAS syndrome.
Seminars in arthritis and rheumatismRefractory fever, pulmonary infiltrates, and auricular chondritis: a rare case of VEXAS syndrome following COVID-19 infection in the emergency department.
World journal of emergency medicineExploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping review.
EClinicalMedicineFatal haemorrhage in VEXAS syndrome: a lethal complication unveiled.
BMJ case reportsA Novel Case of Optic Disc Edema Associated With VEXAS Syndrome.
Journal of vitreoretinal diseasesVEXAS syndrome-associated tumefactive demyelination.
Journal of neurologyVexas Syndrome in a Moroccan Patient: The Story of a Two-Year Diagnostic Lag.
European journal of case reports in internal medicineVacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome With Multisystem Involvement: Imaging and Genetic Insights From a Case Report.
CureusCharacterization of E1 enzyme dependencies in mutant-UBA1 human cells reveals UBA6 as a novel therapeutic target in VEXAS syndrome.
LeukemiaMomelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry.
European journal of haematologyDisease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies.
Annals of the rheumatic diseasesErythematous Plaques and Systemic Inflammation in VEXAS Syndrome.
Deutsches Arzteblatt internationalClinical features in VEXAS syndrome: a systematic review.
Rheumatology (Oxford, England)VEXAS Syndrome and Alzheimer's Disease-Are There Connections?
Brain sciencesInfections in VEXAS syndrome: a systematic review of the literature.
Current research in translational medicineGenetic Basis of Autoinflammatory Skin Diseases. Part I. Genetic Pathways of Complex Autoinflammatory Skin Diseases.
Journal of the American Academy of Dermatology[A CASE OF VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC (VEXAS) SYNDROME PRESENTING WITH DIVERSE PULMONARY LESIONS OVER TIME].
Arerugi = [Allergy]Unravelling VEXAS syndrome: shedding light on a recently recognised medical condition.
BMJ case reportsClonal dominance: mutations in VEXAS syndrome take advantage of inflammation.
Nature reviews. RheumatologyEfficacy of erythroid-stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group.
HemaSphereSolid organ neoplasms in a patient with VEXAS syndrome.
Medicina clinicaUnveiling VEXAS Syndrome: When Skin Manifestations and Monoclonal Gammopathy Precede Myeloid-Lineage Hematologic Abnormality.
ACR open rheumatologyKidney involvement in VEXAS syndrome: insights from a rare case of secondary amyloidosis and systematic review of renal biopsy-confirmed reports.
Clinical rheumatologyVacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: A comprehensive review of cases across different ethnicities.
European journal of internal medicineBone Marrow Vacuolization at the Crossroads of Specialties: Molecular Insights and Diagnostic Challenges.
European journal of haematologyA series of cutaneous manifestations in a patient with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome.
SAGE open medical case reportsRapid clinical deployment of UBA1 testing in patients with VEXAS syndrome.
American journal of clinical pathologyVEXAS syndrome caused by a UBA1 mutation is complicated by recurrent infections leading to hemophagocytic lymphohistiocytosis.
Genes & diseasesMapping VEXAS-associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population.
British journal of haematologyTreatment outcomes in patients with VEXAS syndrome: a retrospective cohort study.
The Lancet. RheumatologyTreatment outcomes in VEXAS syndrome: response is in the eye of the definer.
The Lancet. RheumatologyRecapitulation of clinical features in a patient-derived xenograft mouse model of VEXAS syndrome.
Rheumatology (Oxford, England)Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome.
Expert review of hematologyIn depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome.
Nature communicationsBilateral Alternate Orbital and Ocular Manifestations in a VEXAS Syndrome Patient.
Ocular immunology and inflammationEfficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.
BloodThe pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis.
Nature reviews. RheumatologyReal-world outcomes of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome at a tertiary referral centre.
British journal of haematologyErythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort.
British journal of haematologyBilateral Intraretinal Hemorrhages in VEXAS Syndrome.
Ophthalmology. RetinaVEXAS Syndrome: An Overlooked Threat.
Balkan medical journalNeutrophilic Urticarial Dermatosis: A Window into Systemic Inflammation and Autoimmune Disorders.
Clinical reviews in allergy & immunologyAn Atypical Presentation of VEXAS Syndrome: A Diagnostic Conundrum.
The Ulster medical journalVEXAS syndrome: A newly identified X-Linked hematoinflammatory disorder - A comprehensive overview of its genetic, molecular, inflammatory, and clinical landscape.
Journal of autoimmunityVEXAS Syndrome: Phenotype Alteration in the Long-Term Disease Duration.
International journal of rheumatic diseasesEmerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis.
Annals of hematologyCase Report: Disseminated Nontuberculous Mycobacterial Infection in a VEXAS Syndrome Patient-Possible Association With Variant Allele Frequency.
International journal of rheumatic diseasesVEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome.
Practical neurologyClinical features and treatments of VEXAS syndrome in critical care: a scoping review.
Critical care (London, England)Rapid Screening and Monitoring of UBA1 Mutations in VEXAS Syndrome.
The Journal of molecular diagnostics : JMDNew X for VEXAS: haploidentical allogeneic haematopoietic cell transplantation in VEXAS syndrome.
Rheumatology (Oxford, England)Inflammation and disrupted hematopoiesis drive clonal dominance in a mouse model of VEXAS syndrome.
Nature medicineMyeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single-centre experience.
British journal of haematologyMechanisms of hematopoietic clonal dominance in VEXAS syndrome.
Nature medicineA Case of VEXAS Syndrome Presenting with Unexplained Headache.
Turkish journal of haematology : official journal of Turkish Society of HaematologyTherapeutic Challenges in the Management of VEXAS Syndrome: A Case Report.
The Australasian journal of dermatologyThe Challenging and Unique Diagnosis of VEXAS Syndrome: A Case Report.
Journal of investigative medicine high impact case reportsFatigue and chronic anaemia: Could it be VEXAS syndrome?
Australian journal of general practiceHistiocytoid Sweet Syndrome as a Manifestation of Myelodysplasia Cutis/Cutaneous VEXAS Syndrome.
The American Journal of dermatopathology[A case report of VEXAS syndrome].
Zhonghua nei ke za zhiOcular Features of VEXAS Syndrome: A Systematic Review and Meta-analysis.
American journal of ophthalmologyIs it VEXAS or is it vasculitis?
Clinical and experimental rheumatologySystemic vasculitis: one year in review 2025.
Clinical and experimental rheumatology[VEXAS- NEWLY REPORTED SYNDROME WITH OCULAR MANIFESTATIONS: CASE REPORT].
HarefuahVEXAS syndrome: a Swiss national retrospective cohort study.
Swiss medical weeklyVacuoles, E1 Enzyme, X-linked, Autoinflammatory, and Somatic (VEXAS) Syndrome: A Diagnostic and Therapeutic Conundrum.
CureusEfficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network.
Frontiers in pharmacologyKaposi sarcoma posthematopoietic stem cell transplant for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome.
JAAD case reportsAltered IgG4 serum levels in VEXAS syndrome - a retrospective monocentric cohort study.
Rheumatology internationalVEXAS syndrome with p.Met41Leu UBA1 gene mutation misdiagnosed as tumid lupus: A series of 3 cases.
JAAD case reportsCritical cardiovascular complications during non-immunosuppressive therapy for VEXAS syndrome.
Rheumatology advances in practiceVEXAS associated acute disseminated Encephalo-Myelitis (ADEM)-like syndrome: A case report and review of the literature.
Current research in translational medicine[VEXAS syndrome - a chameleon of inflammatory syndromes].
PraxisInflammatory Signatures in VEXAS Syndrome, Myelodysplasia Cutis, and Sweet Syndrome.
JAMA dermatologyVEXAS Syndrome: A Perspective Focus on Genetics and Hematological Manifestations.
Genetic testing and molecular biomarkersAortitis in VEXAS Syndrome.
Internal medicine (Tokyo, Japan)Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry.
Frontiers in pharmacologyVacuoles, E1 Enzyme, X-linked, Autoinflammatory, and Somatic (VEXAS) Syndrome: A Case Report.
CureusDecoding Cytoplasmic Vacuolization: Unraveling the Diagnostic Challenges of VEXAS Syndrome.
Turkish journal of haematology : official journal of Turkish Society of HaematologyVEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort.
Rheumatology (Oxford, England)This month in JAAD Case Reports: April 2025.
Journal of the American Academy of DermatologyNeurological manifestations in patients with VEXAS syndrome.
Journal of neurologyVery long-term remission with azacitidine in VEXAS syndrome.
HaematologicaVEXAS, Chediak-Higashi syndrome and Danon disease: myeloid cell endo-lysosomal pathway dysfunction as a common denominator?
Cellular & molecular biology lettersImproving outcomes in VEXAS syndrome: the need for prospective data.
Rheumatology (Oxford, England)VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management.
Annals of hematologyJAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib.
British journal of haematologyA Clinicopathological Description of Kidney Features in VEXAS Syndrome.
Kidney international reportsA case of VEXAS syndrome with therapy refractive macular involvement.
Canadian journal of ophthalmology. Journal canadien d'ophtalmologieHypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics.
British journal of haematologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Síndrome VEXAS.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Síndrome VEXAS
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Inflammatory cell death and monocyte dysfunction in VEXAS syndrome.
- VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
- Reversal of third-degree AV block with ruxolitinib in VEXAS-associated myocarditis: a case report.
- Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome.
- Unravelling the cellular mechanisms of VEXAS syndrome.
- VEXAS syndrome.
- VEXAS syndrome.
- Unmasking Vexas Syndrome: A Rare Case with Crescentic Glomerulonephritis.
- When to suspect monogenic autoinflammatory diseases in patients with digestive symptoms?
- Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:596753(Orphanet)
- OMIM OMIM:301054(OMIM)
- MONDO:0026777(MONDO)
- GARD:15001(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Artigo Wikipedia(Wikipedia)
- Q102294972(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
